The $200m corporate venturing unit of Baxter International, Baxter Ventures, leads a $38m B round into Naurex, a US-based drug developer which has received technologies from Northwestern University.
Baxter Ventures, established by the drug company Baxter International, has led a $38m Series B round into Naurex, a clinical-stage drug company developing treatments in psychiatry and neurology that utilises treatments developed at Northwestern University.
Naurex’s treatments are developed from the work of Joseph R. Moskal and his colleagues at the Falk Center for Molecular Therapeutics at Northwestern University.
The round also saw involvement from existing investors, private equity investment firm Adams Street Partners, Latterell Venture Partners, Genesys Capital, PathoCapital, Druid Bioventures and…
